Joel Hockensmith
About
We are employing chemical control of DNA-dependent ATP hydrolysis to control epigenetic and chromatin remodelling as a novel protozoan therapeutic target for diseases such as malaria, amebic dysentery, Leishmaniasis and others.
Collaborators
